Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

PURPOSE The Berlin-Frankfurt-Munster (BFM) 76/79 trial of acute lymphoblastic leukemia (ALL) in children produced impressive disease-free survival (DFS) rates with a protocol that began with 8 weeks of intensive therapy, followed by 8 weeks of maintenance therapy, and then another 6 weeks of intensive treatment. The current study was conducted to determine the relative contributions of each of these periods of intense therapy on the DFS rates of ALL patients with intermediate presenting features. In addition, due to concerns regarding the toxicity of CNS irradiation, we compared cranial irradiation (CXRT) with intrathecal methotrexate (IT MTX) administered during induction and consolidation to IT MTX during all phases of the treatment program. PATIENTS AND METHODS Between May 1983 and April 1989, more than 1,600 children with ALL and intermediate presenting features, as defined by the Childrens Cancer Group (CCG), were entered into a randomized trial that tested four systemic therapy regimens and two CNS programs. RESULTS The results with a median follow-up of 57 months show that systemic regimens with a delayed intensification (Delint) phase of therapy had a 5-year event-free survival (EFS) rate of 73% compared with the control regimen EFS rate of 61% (p = .006). For children less than 10 years of age, standard three-drug induction and Delint produced a 77% 5-year EFS. IT MTX during all phases of therapy provided CNS protection comparable to the CXRT regimen in children less than 10 years of age. Children 10 years of age or older appear to have a better EFS rate with intensive induction, Delint, and CXRT. CONCLUSION Delint improves the EFS rate of children with ALL and intermediate presenting features. Maintenance IT MTX can be safely substituted for CXRT for presymptomatic CNS therapy in children with intermediate-risk characteristics less than 10 years of age.

[1]  R. Gale,et al.  Acute lymphoblastic leukemia: recent advances in biology and therapy. , 1989, Blood.

[2]  L. Freedman,et al.  The size of clinical trials in cancer research--what are the current needs? Medical Research Council Cancer Therapy Committee. , 1989, British Journal of Cancer.

[3]  C. Spurr,et al.  Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia. , 1985, Seminars in oncology.

[4]  M. Gail,et al.  Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.

[5]  Bleyer Wa,et al.  Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. , 1985 .

[6]  W. Willett,et al.  The 2 × 2 factorial design: Its application to a randomized trial of aspirin and U.S. physicians , 1985 .

[7]  A. Bleyer,et al.  Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). , 1984, International journal of radiation oncology, biology, physics.

[8]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[9]  P. Dyment,et al.  Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study , 1982 .

[10]  T C Chalmers,et al.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.

[11]  R. Peto,et al.  Clinical trial methodology , 1978, Nature.

[12]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[13]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[14]  R. Aur,et al.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. , 1971, Blood.

[15]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  G. Henze,et al.  Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.

[18]  J. Ochs,et al.  Neurotoxicity due to central nervous system therapy for childhood leukemia. , 1989, The American journal of pediatric hematology/oncology.

[19]  C. Pui,et al.  Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: analysis by contemporary risk classifications. , 1988, Blood.

[20]  H. Sather,et al.  Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. , 1988, The American journal of pediatric hematology/oncology.

[21]  L. Rorke,et al.  Long-term sequelae of cancer treatment on the central nervous system in childhood. , 1987, Medical and pediatric oncology.

[22]  A. Bleyer,et al.  Analysis of prognostic factors in acute lymphoblastic leukemia. , 1986, Medical and pediatric oncology.

[23]  S. Piantadosi,et al.  Factorial designs for randomized clinical trials. , 1985, Cancer treatment reports.

[24]  R W Makuch,et al.  Sample size requirements for comparing time-to-failure among k treatment groups. , 1982, Journal of chronic diseases.